1. Feinberg JI, Schrott R, Ladd-Acosta C, Newschaffer CJ, Hertz-Picciotto I, Croen LA et al. Epigenetic changes in sperm are associated with paternal and child quantitative autistic traits in an autism-enriched cohort. Mol Psychiatry. 2023. https://doi.org/10.1038/s41380-023-02046-7.
2. New Zealand Medicines and Medical Devices Safety Authority. Safety Information. Alert communication. Sodium valproate (Epilim) use in people who can father children: important new safety information. 2023 https://www.medsafe.govt.nz/safety/Alerts/Sodium_valproate_Epilim_use_in_people_who_can_father_children.asp. Accessed Jun 2023.
3. Bierrenbach AL. EUPAS34201. A post-authorization safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorders as well as congenital abnormalities in offspring – a population-based retrospective study. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. First registered on: 30 Apr 2020. Last updated on: 17 May 2023. https://www.encepp.eu/encepp/viewResource.htm;jsessionid=YBeBY4EYJfo8GGj2hv0_zVgvp_naBOkPXCr5OarjS6N0NmvL-TI_!-1928679420?id=50599. Accessed June 2023.
4. Petronis A, Gottesman II, Crow TJ, DeLisi LE, Klar AJ, Macciardi F, et al. Psychiatric epigenetics: a new focus for the new century. Mol Psychiatry. 2000;5:342–6. https://doi.org/10.1038/sj.mp.4000750.
5. Christianson AL, Chesler N, Kromberg JG. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol. 1994;36:361–9. https://doi.org/10.1111/j.1469-8749.1994.tb11858.x.